|
1
|
Shah NP, Pajidipati NJ, McGarrah RW, Navar
AM, Vemulapalli S, Blazing MA, Shah SH, Hernandez AF and Patel MR:
Lipoprotein (a): An update on a marker of residual risk and
associated clinical manifestations. Am J Cardiol. 126:94–102.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Seed M, Ayres KL, Humphries SE and Miller
GJ: Lipoprotein (a) as a predictor of myocardial infarction in
middle-aged men. Am J Med. 110:22–27. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Konishi H, Miyauchi K, Kasai T, Tsuboi S,
Ogita M, Naito R, Sai E, Fukushima Y, Katoh Y, Okai I, et al:
Impact of lipoprotein(a) as residual risk on long-term outcomes in
patients after percutaneous coronary intervention. Am J Cardiol.
115:157–160. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Abe A and Noma A: Studies on
apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a
healthy Japanese population. Atherosclerosis. 96:1–8.
1992.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ikenaga H, Ishihara M, Inoue I, Kawagoe T,
Shimatani Y, Miura F, Nakama Y, Dai K, Otani T, Ejiri K, et al:
Usefulness of lipoprotein (a) for predicting progression of
non-culprit coronary lesions after acute myocardial infarction.
Circ J. 75:2847–2852. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nordestgaard BG and Langsted A:
Lipoprotein (a) as a cause of cardiovascular disease: Insights from
epidemiology, genetics, and biology. J Lipid Res. 57:1953–1975.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tsarouhas K, Tsitsimpikou C, Haliassos A,
Georgoulias P, Koutsioras I, Kouretas D, Kogias J, Liosis I,
Rentoukas E and Kyriakides Z: Study of insulin resistance, TNF-α,
total antioxidant capacity and lipid profile in patients with
chronic heart failure under exercise. In Vivo. 25:1031–1037.
2011.PubMed/NCBI
|
|
8
|
Clarke R, Peden JF, Hopewell JC, Kyriakou
T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, et
al: Genetic variants associated with Lp(a) lipoprotein level and
coronary disease. N Engl J Med. 361:2518–2528. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kamstrup PR, Tybjaerg-Hansen A, Steffensen
R and Nordestgaard BG: Genetically elevated lipoprotein(a) and
increased risk of myocardial infarction. JAMA. 301:2331–2339.
2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Randall OS, Feseha HB, Illoh K, Xu S,
Ketete M, Kwagyan J, Tilghman C and Wrenn M: Response of
lipoprotein(a) levels to therapeutic life-style change in obese
African-Americans. Atherosclerosis. 172:155–160. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Teng RL, Wang H, Sun BC, Cai DP and He YM:
Interaction between lipoprotein (a) levels and body mass index in
first incident acute myocardial infarction. BMC Cardiovasc Disord.
20(350)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grainger DJ, Kirschenlohr HL, Metcalfe JC,
Weissberg PL, Wade DP and Lawn RM: Proliferation of human smooth
muscle cells promoted by lipoprotein(a). Science. 260:1655–1658.
1993.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wilson DP, Jacobson TA, Jones PH,
Koschinsky ML, McNeal CJ, Nordestgaard BG and Orringer CE: Use of
lipoprotein(a) in clinical practice: A biomarker whose time has
come. A scientific statement from the national lipid association. J
Clin Lipidol. 13:374–392. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tsimikas S and Hall JL: Lipoprotein(a) as
a potential causal genetic risk factor of cardiovascular disease: A
rationale for increased efforts to understand its pathophysiology
and develop targeted therapies. J Am Coll Cardiol. 60:716–721.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Terres W, Tatsis E, Pfalzer B, Beil FU,
Beisiegel U and Hamm CW: Rapid angiographic progression of coronary
artery disease in patients with elevated lipoprotein(a).
Circulation. 91:948–950. 1995.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Reyes-Soffer G, Ginsberg HN, Berglund L,
Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM,
Yeang C, Koschinsky ML, et al: Lipoprotein(a): A genetically
determined, causal, and prevalent risk factor for atherosclerotic
cardiovascular disease: A scientific statement from the American
heart association. Arterioscler Thromb Vasc Biol. 42:e48–e60.
2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schreml J and Gouni-Berthold I:
Apolipoprotein(a) antisense oligonucleotides: A new treatment
option for lowering elevated lipoprotein(a)? Curr Pharm Des.
23:1562–1570. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Viney NJ, van Capelleveen JC, Geary RS,
Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke
RM, et al: Antisense oligonucleotides targeting apolipoprotein(a)
in people with raised lipoprotein(a): Two randomised, double-blind,
placebo-controlled, dose-ranging trials. Lancet. 388:2239–2253.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Madsen CM, Kamstrup PR, Langsted A, Varbo
A and Nordestgaard BG: Lipoprotein(a)-lowering by 50 mg/dl (105
nmol/l) may be needed to reduce cardiovascular disease 20% in
secondary prevention: A population-based study. Arterioscler Thromb
Vasc Biol. 40:255–266. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mitsuda T, Uemura Y, Ishii H, Takemoto K,
Uchikawa T, Koyasu M, Ishikawa S, Miura A, Imai R, Iwamiya S, et
al: Lipoprotein(a) levels predict adverse vascular events after
acute myocardial infarction. Heart Vessels. 31:1923–1929.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Taleb A, Witztum JL and Tsimikas S:
Oxidized phospholipids on apoB-100-containing lipoproteins: A
biomarker predicting cardiovascular disease and cardiovascular
events. Biomark Med. 5:673–694. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Verbeek R, Hoogeveen RM, Langsted A,
Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT,
Boekholdt SM, Nordestgaard BG and Stroes ESG: Cardiovascular
disease risk associated with elevated lipoprotein(a) attenuates at
low low-density lipoprotein cholesterol levels in a primary
prevention setting. Eur Heart J. 39:2589–2596. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Dilba K, van Dijk AC, Crombag GAJC, van
der Steen AFW, Daemen MJ, Koudstaal PJ, Nederkoorn PJ, Hendrikse J,
Kooi ME, van der Lugt A and Wentzel JJ: Association between
intraplaque hemorrhage and vascular remodeling in carotid arteries:
The plaque at RISK (PARISK) study. Cerebrovasc Dis. 50:94–99.
2021.PubMed/NCBI View Article : Google Scholar
|
